Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06423872
Status:
COMPLETED
Last Update Posted:
2024-05-21
First Post:
2024-05-16
Brief Title:
A SAD Study of ZT002 Injection in Healthy Participants
Sponsor:
Beijing QL Biopharmaceutical CoLtd
Organization:
Beijing QL Biopharmaceutical CoLtd
Study Overview
Official Title:
A Phase 1 Randomized Parallel Assignment Double Blind Placebo Controlled Single and Multiple Ascending Dose Safety Tolerability and Pharmacokinetic Study of ZT002 in Healthy Participants
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will comprise a randomized parallel assignment double blind placebo controlled single and multiple ascending dose safety tolerability and pharmacokinetic study of ZT002 in healthy participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None